Filing Analysis
Regulation FD Disclosure
Filed May 07, 2026
LOW
Korro Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as Exhibit 99.1.
Red Flags
- The CEO (Ram Aiyar) is also serving as the Interim CFO, indicating a vacancy in a key executive financial position.
Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 7, 2026.
- Ram Aiyar is currently serving as President, Chief Executive Officer, and Interim Chief Financial Officer.
Regulation FD Disclosure
Filed Mar 12, 2026
LOW
Korro Bio, Inc. announced its financial results for the fiscal year ended December 31, 2025. The disclosure was made via a press release furnished as an exhibit to the filing.
Red Flags
- CEO Ram Aiyar is also serving as Interim CFO, indicating a lack of a dedicated permanent Chief Financial Officer.
Key Facts
- Financial results reported for the full year ended December 31, 2025
- Report filed on March 12, 2026
- Ram Aiyar is currently serving as President, CEO, and Interim Chief Financial Officer
- Information furnished under Item 2.02 is not deemed 'filed' for Section 18 liability purposes
Securities Offering
Filed Mar 09, 2026
MEDIUM
Korro Bio, Inc. entered into a subscription agreement for a private placement (PIPE) to raise approximately $85.0 million in gross proceeds through the sale of common stock and pre-funded warrants. The financing, led by Venrock Healthcare Capital Partners, is expected to extend the company's cash runway into the second half of 2028.
Red Flags
- The CEO is currently serving as the Interim CFO, indicating a vacancy in a key executive position.
- The registration rights agreement includes liquidated damages provisions if deadlines for filing or effectiveness are not met.
- The offering is a private placement (PIPE), which is typically dilutive to existing shareholders.
Key Facts
- Agreement to sell 4,501,928 shares of common stock at $11.11 per share.
- Agreement to sell 3,148,836 pre-funded warrants at $11.109 per warrant with an exercise price of $0.001.
- Gross proceeds of approximately $85.0 million before commissions and expenses.
- Participation from institutional investors including Venrock, ADAR1 Capital Management, Balyasny Asset Management, and New Enterprise Associates.
- Preliminary cash, cash equivalents, and marketable securities of $85.2 million as of December 31, 2025.
- Company must file a resale registration statement within 30 days of closing and cause it to be effective within 60-90 days.
- Ram Aiyar is currently serving as both President/CEO and Interim Chief Financial Officer.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.